Cyclic dibutyryl AMP | 362-74-3

• 物质功能分类: 生物化工 - 核苷类药物 - 核苷中间体
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: Cyclic dibutyryl AMP
• 英文别名: [6-[6-(butanoylamino)purin-9-yl]-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate
• CAS: 362-74-3
• 化学式: C₁₈H₂₄N₅O₈P
• 分子量: 469.4
• InChiKey: CJGYSWNGNKCJSB-UHFFFAOYSA-N

物化性质

• 密度：
  1.72±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于二甲基亚砜；甲烷

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  164
• 氢给体数：
  2
• 氢受体数：
  11

安全信息

• 储存条件：
  室温

制备方法与用途

二丁基环磷腺苷是化学合成的环磷腺苷衍生物，属于蛋白激酶激活剂。它对细胞具有较强的渗透性，并能调节细胞的多种功能活动。

文献信息

• Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof
  申请人：Mikamiyama Hidenori

  公开号：US20110136833A1

  公开（公告）日：2011-06-09

  The invention relates to tetrahydropyridinyl and dihydropyrrolyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X, Y, Z, R 1 , R 2 , m, and n are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

  这项发明涉及式(I)的四氢吡啶基和二氢吡咯基化合物，以及其药学上可接受的盐、前药或溶剂化合物，其中X、Y、Z、R1、R2、m和n的定义如规范中所述。该发明还涉及利用式(I)的化合物治疗对钙通道阻滞有反应的疾病，特别是N型钙通道。本发明的化合物特别适用于治疗疼痛。
• 4-phenylsulfonamidopiperidines as calcium channel blockers
  申请人：Benjamin Elfrida R.

  公开号：US20090105249A1

  公开（公告）日：2009-04-23

  The invention relates to piperidinyl compounds of Formula (I): or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R 1 -R 3 and Z are defined as set forth in the specification. The invention is also directed to an assay useful for identifying such compounds as N-type calcium channel modulators or blockers. The invention is also directed to the compounds of Formula (I) and compounds identified by the above assay, and the use of such compounds to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

  该发明涉及式(I)的哌啶基化合物：或其药用可接受的盐、前药或溶剂，其中R1-R3和Z如规范中所述。该发明还涉及一种用于识别此类化合物作为N-型钙通道调节剂或阻断剂的测定方法。该发明还涉及式(I)的化合物和通过上述测定方法鉴定的化合物，以及使用这些化合物来治疗、预防或改善对钙通道阻断作出反应的疾病，尤其是N-型钙通道。本发明的化合物特别适用于治疗疼痛。
• Substituted benzimidazoles
  申请人：Gant Thomas G.

  公开号：US20090258897A1

  公开（公告）日：2009-10-15

  Disclosed herein are substituted benzimidazole-based proton pump modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本文揭示了一种基于苯并咪唑的质子泵调节剂的化合物I，其制备方法，药物组合物及使用方法。
• [EN] OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF<br/>[FR] COMPOSÉS OXYCARBAMOYLE ET LEUR UTILISATION
  申请人：SHIONOGI & CO

  公开号：WO2009151152A1

  公开（公告）日：2009-12-17

  The invention relates to oxycarbamoyl compounds of Formula I: The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockadeof calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

  这项发明涉及到化合物的氧羰基化合物的化学式I：该发明还涉及使用化合物的化学式I来治疗、预防或改善对钙通道阻滞有反应的疾病，尤其是N-型钙通道。本发明的化合物特别适用于治疗疼痛。
• HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Schmidt Fanny

  公开号：US20110118270A1

  公开（公告）日：2011-05-19

  The present invention relates to compounds of Formula (I) below, to their pharmaceutically acceptable salts and to their isomers or mixtures of isomers: HetAr—X—CHR 1 R 2 (I) in which: -HetAr represents a group chosen from: —X represents a linear, saturated or unsaturated, hydrocarbon-based chain comprising from 8 to 22 carbon atoms, optionally interrupted by an —NH— or —NH—CO— group, —R 1 represents a hydrogen atom or an —OH, —O(C 1 -C 6 )alkyl, —OCO((C 1 -C 6 )alkyl), —OSO 2 ((C 1 -C 6 )alkyl) or —OSO 3 H group, and —R 2 represents a hydrogen atom or a (C 2 -C 6 )alkynyl, (C 2 -C 6 )alkenyl or (C 3 -C 6 )cycloalkyl group. The present invention also relates to a process for preparing the compounds of Formula (I), and also to the use thereof, especially in the treatment of neurodegenerative diseases.

  本发明涉及以下化合物的化学式(I)，其药学上可接受的盐以及它们的异构体或异构体混合物：HetAr—X—CHR1R2(I)其中：-HetAr代表从中选择的一个基团：-X代表由8到22个碳原子组成的线性、饱和或不饱和的基于碳的链，可选地被一个—NH—或—NH—CO—基团中断，-R1代表氢原子或—OH，—O(C1-C6)烷基，—OCO((C1-C6)烷基)，—OSO2((C1-C6)烷基)或—OSO3H基团，-R2代表氢原子或(C2-C6)炔基，(C2-C6)烯基或(C3-C6)环烷基基团。本发明还涉及一种制备化学式(I)化合物的方法，以及其用途，特别是在治疗神经退行性疾病方面。